Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 05, 2004. The report details a share repurchase transaction executed on November 03, 2004, and updates regarding directors' interests in company shares and employee benefit plans.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The specific financial data disclosed relates to capital structure and share transactions:
- Share Repurchase: 500,000 ordinary shares purchased at 1,185.33 pence per share.
- Treasury Shares: Total holdings increased to 49,978,000 shares.
- Shares in Issue: 5,885,998,623 shares (excluding Treasury shares).
- US Retirement Plan Valuation: Notional investment re-valued at $44.37 per share ADR.
Material Changes
The primary material change reported is the reduction of outstanding shares through the open market purchase of 500,000 shares, which were subsequently held in Treasury. Additionally, there were minor adjustments to directors' notional interests in the US Retirement Savings Plan due to fund movements and share transfers from the GSK Trust to employee plan participants.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a routine disclosure of corporate actions and director interest changes. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase against the reported price of 1,185.33 pence.
- Confirm the updated total share count of 5,885,998,623 in issue.
- Note that the repurchase was authorized by shareholders at the Annual General Meeting on May 17, 2004.
- Review the specific changes in notional ADR holdings for Directors Dr. J-P Garnier and Dr. T Yamada within the US Retirement Savings Plan.